7 completed, 2 terminated, 1 unknown, 1 withdrawn. 8 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Completed 4, Terminated 2, Unknown 1, Withdrawn 1 |
| Phase 1 | 5 | Completed 3, Terminated 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow Varlitinib: new trials by email Literature Review of Varlitinib trials Research Report on Varlitinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine - Advanced or Metastatic Biliary Tract Cancer | Phase 2 | Withdrawn | ASLAN Pharmaceuticals | 2018-05-01 | 2018-05-23 | |
| Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine - Biliary Tract Cancer | Phase 2 | Completed | ASLAN Pharmaceuticals | 62 | 2017-12-19 | 2020-11-19 |
| Open, Single-dose/-Period Study to Assess Mass Balance Recovery, Metabolite Profile/Identification of 14C-Varlitinib Varlitinib - Healthy Volunteers | Phase 1 | Completed | ASLAN Pharmaceuticals | 6 | 2017-11-23 | 2018-09-11 |
| Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) Varlitinib, mFOLFOX6, Placebo - Gastric Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 52 | 2017-08-31 | 2022-02-15 |
| Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Varlitinib, Capecitabine, Placebo (for Varlitinib) - Biliary Tract Cancer | Phase 2 / Phase 3 | Completed | ASLAN Pharmaceuticals | 151 | 2017-07-04 | 2021-08-03 |
| Phase 1b of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) ASLAN001 - Advanced/ Metastatic Hepatocellular Carcinoma | Phase 1 / Phase 2 | Unknown | National University Hospital, Singapore | 22 | 2017-05-05 | 2018-04-17 |
| A Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours varlitinib, capecitabine - Advanced or Metastatic Biliary Tract Cancer, Advanced or Metastatic Solid Tumors | Phase 1 | Completed | ASLAN Pharmaceuticals | 24 | 2017-01-31 | 2018-06-28 |
| Varlitinib in Combination With Gemcitabine and Cisplatin for Treatment naïve Advanced or Metastatic BTC Varlitinib, Cisplatin, Gemcitabine - Biliary Tract Cancer | Phase 1 / Phase 2 | Terminated | ASLAN Pharmaceuticals | 204 | 2016-12-13 | 2021-01-14 |
| Phase II Study to Assess the Efficacy of ASLAN001 Plus Capecitabine in CNS Metastases for HER2+ Breast Cancer ASLAN001, Capecitabine - HER2-positive Breast Cancer | Phase 2 | Terminated | National Cancer Centre, Singapore | 3 | 2016-08-11 | 2025-09-10 |
| ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy Varlitinib - Cholangiocarcinoma | Phase 2 | Completed | ASLAN Pharmaceuticals | 32 | 2015-11-16 | 2018-05-29 |
| Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-FU or Cisplatin and Capecitabine ASLAN001, cisplatin + capecitabine, cisplatin + 5-fluorouracil (or+ Leucovorin) - Solid Tumor | Phase 1 | Completed | ASLAN Pharmaceuticals | 31 | 2014-08-05 | 2018-10-25 |
Biliary Tract Neoplasms (5) · Bile Duct Neoplasms (2) · Gallbladder Neoplasms (2) · Cholangiocarcinoma (1) · Neoplasms (1) · Stomach Neoplasms (1)
ASLAN Pharmaceuticals (9) · National Cancer Centre, Singapore (1) · National University Hospital, Singapore (1)
Singapore (6) · Taiwan (5) · South Korea (4) · Hong Kong (3) · China (2) · Japan (2) · Australia (1) · Estonia (1) · Hungary (1) · Lithuania (1) · Malaysia (1) · Poland (1) · Spain (1) · Thailand (1) · United Kingdom (1)
Raghav Sundar (1) · Yoon Sim Yap (1)
2016 (1)